Prostate Cancer
Conditions
Keywords
Androgen Independent Prostate Cancer
Brief summary
Subjects who qualify will receive single agent oral lenalidomide daily on days 1-21 every 28 day cycle. Subjects will continue on study until documented disease progression
Interventions
DRUGCC5013
Sponsors
Prologue Research International
Celgene Corporation
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Understand and voluntarily sign an informed consent form. 2. Age \> or = to 18 years at the time of signing the informed consent form. 3. Able to adhere to the study visit schedule and other protocol requirements. 4. Must have a histologic diagnosis of adenocarcinoma of the prostate. 5. Must be surgically or medically castrated. If the method is medical castration, the subject must have a serum testosterone level of \<50 ng/dl. The subject should maintain treatment with LH RH antagonists or agonists. 6. Must have prostate cancer unresponsive or refractory to androgen blockade as demonstrated by rising PSA. -Rising PSA is defined as at least 2 consecutive rises in PSA to be documented over the reference value (measure 1). The first rising PSA (measure 2) must be taken at least 7 days after the reference value. A third confirmatory PSA is required, and it must be obtained at least seven days after the second measure. If this is not greater than measure 2, a fourth PSA is required and this must be greater than measure 2. -Absolute value of PSA \> or = to 5 ng/ml on the last confirmatory assessment. 7. Prior treatment with antiandrogens such as flutamide, or other hormonal agents such as estrogens, corticosteroids, or ketoconazole must have been stopped for at least 28 days prior to treatment. In the case of nilandron and bicalutamide, treatment with these agents must have stopped at least 42 days prior to treatment. Following completion of the antiandrogen withdrawal period, either: * One post withdrawal PSA value must be higher than the last pre-withdrawal PSA value, or * If the subject's PSA value decreased following the antiandrogen withdrawal period then two increases in PSA values must be documented after the post-withdrawal nadir. 8. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 (Appendix II: ECOG Performance Status Scale).
Exclusion criteria
1. Metastatic prostate cancer 2. Any of the following laboratory abnormalities: 1. Absolute neutrophil count (ANC) \<1,500 cells/mm3 (1.5 x 109/L) 2. Platelet count \<100,000 cells/mm3 (100 x 109/L) 3. Serum creatinine \>2.5 mg/dL (221 mmol/L) 4. Serum SGOT/AST or SGPT/ALT \>3.0 x upper limit of normal (ULN) 5. Serum total bilirubin \>2.0 mg/dL (34 mmol/L) 3. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he were to participate in the study or confounds the ability to interpret data from the study. 4. Prior history of malignancies other than AIPC (except for basal cell or squamous cell carcinoma of the skin) unless the subject has been free of the disease for \> or = to 1 year. 5. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form. 6. Prior \> or = to grade 3 allergic reaction/hypersensitivity to thalidomide. 7. Prior \> or = to grade 3 rash or any desquamating (blistering) rash while taking thalidomide. 8. Prior use of lenalidomide. 9. Prior use of chemotherapy for androgen independent prostate cancer. 10. Use of any standard/experimental anti-cancer drug therapy within 28 days of the initiation of study drug therapy except LHRH agonists/antagonists. 11. Known active Hepatitis C.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the activity of lenalidomide monotherapy in subjects with androgen independent prostate cancer (AIPC). | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the safety of lenalidomide monotherapy as treatment for subjects with AIPC. | — |
Countries
United States
Outcome results
None listed